文献速递白内障与屈光手术

ACE抑制剂使用与白内障风险:病例对照分析

ACE inhibitor use and risk of cataract: a case-control analysis.
PubMed 文献 · Br J Ophthalmol · 2019-02-07

主要分析显示ACEI使用与白内障风险无实质性改变(OR 1.06,95%CI 1.04-1.08),敏感性及分层分析结果一致。

要点

  • ACEI使用与白内障风险无实质性关联(OR 1.06,95%CI 1.04-1.08)。
  • 敏感性及分层分析均未改变主要结论。
  • 研究样本量大,基于英国CPRD数据库。

核心结论

  • 在这项大型观察性研究中,ACEI使用与白内障风险改变无关。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)的病例对照研究。
  • 纳入1995至2015年间年龄≥40岁的首次白内障患者及等量无白内障对照,按年龄、性别、全科诊所、首次白内障日期及CPRD历史年限匹配。

主要发现

  • 与未使用ACEI相比,ACEI使用与白内障风险无实质性改变(主要分析OR 1.06,95%CI 1.04-1.08)。
  • 敏感性分析及分层分析结果与主要分析一致。

关键数值与推荐

  • 主要分析中ACEI暴露与白内障风险的OR为1.06(95%CI 1.04-1.08)。
  • 多变量模型调整了体重指数、吸烟、糖尿病、高血压、全身性皮质类固醇处方及其他降压药处方。

临床怎么用

  • 临床中ACEI使用无需因白内障风险而调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIM: Use of ACE inhibitors (ACEIs) has been associated with an increased risk of cataract in a previous observational study in humans. In contrast, ACEIs were associated with beneficial effects on cataract development in experimental studies. We assessed the risk of cataract in relation to exposure to ACEI and other antihypertensive drugs. METHODS: This is a case-control study based on data from the UK-based Clinical Practice Research Datalink (CPRD). We included first-time cataract patients aged ≥40 years between 1995 and 2015 and an equal number of cataract-free controls. We matched the controls to cases on age, sex, general practice, date of first cataract (ie, index date) and years of history in the CPRD prior to the index date. We assessed the number of prescriptions for ACEI and other antihypertensive drugs in detail and explored the use of single ACEI substances. We performed conditional logistic regression and conducted various sensitivity analyses to test the robustness of our findings. We calculated the risk of cataract associated with previous exposure to ACEI, measured as OR with 95% CIs, and adjusted the multivariable model for body mass index, smoking, diabetes, hypertension, prescriptions of systemic corticosteroids and other antihypertensive drugs. RESULTS: We identified 206 931 cataract cases and the same number of matched controls. Use of ACEI was not associated with a materially altered risk of cataract compared with non-use of ACEI, neither in the main analysis (OR 1.06, 95% CI 1.04 to 1.08) nor in any of the sensitivity or stratified analyses. CONCLUSION: In our large observational study, use of ACEI was not associated with an altered risk of cataract.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Becker C, Jick SS, Meier CR, et al. ACE inhibitor use and risk of cataract: a case-control analysis. Br J Ophthalmol. 2019. PMID: 30733210. doi:10.1136/bjophthalmol-2018-312980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。